☰

Margaret M. McClure, Ph.D. - Publications

Affiliations: 
2005 Fordham University, Bronx, NY, United States 
Area:
Clinical Psychology, Cognitive Psychology
Tree Info Grants Similar researchers PubMed Report error

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Denny BT, Lopez RB, Wu-Chung EL, Dicker EE, Goodson PN, Fan J, Schulz KP, Ochsner KN, Trumbull J, Lopez MM, Fels S, Galitzer H, Perez-Rodriguez M, Goodman M, Rosell DR, ... ... McClure MM, et al. Training in cognitive reappraisal normalizes whole-brain indices of emotion regulation in borderline personality disorder. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. PMID 38641208 DOI: 10.1016/j.bpsc.2024.03.007  0.3
2024 Challman KN, Rosell DR, Barch D, Koenigsberg HW, Harvey PD, Hazlett EA, Perez-Rodriguez MM, New AS, McClure MM. The MATRICS consensus cognitive battery for the assessment of cognitive impairment in schizotypal personality disorder. Schizophrenia Research. 267: 308-312. PMID 38608417 DOI: 10.1016/j.schres.2024.04.007  0.439
2022 Szeszko PR, Gohel S, Vaccaro DH, Chu KW, Tang CY, Goldstein KE, New AS, Siever LJ, McClure M, Perez-Rodriguez MM, Haznedar MM, Byne W, Hazlett EA. Frontotemporal thalamic connectivity in schizophrenia and schizotypal personality disorder. Psychiatry Research. Neuroimaging. 322: 111463. PMID 35240516 DOI: 10.1016/j.pscychresns.2022.111463  0.397
2020 Thompson JL, Rosell DR, Slifstein M, Xu X, Rothstein EG, Modiano YA, Kegeles LS, Koenigsberg HW, New AS, Hazlett EA, McClure MM, Perez-Rodriguez MM, Siever LJ, Abi-Dargham A. Amphetamine-induced striatal dopamine release in schizotypal personality disorder. Psychopharmacology. PMID 32572588 DOI: 10.1007/s00213-020-05561-5  0.309
2020 Lopez MM, Rhodes H, Calabrese W, Lindenmeyer H, Schulz K, McClure M, Rosell D, Hazlet E, New A, Perez-Rodriguez MdlM, Koenigsberg H. Exploring Trust Game Cooperation in Borderline Personality Disorder Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.456  0.319
2020 Torres SF, Smith E, Rutter S, Martinez CB, Calabrese W, Ghavami M, McClure M, Rosell D, Koenigsberg H, Hazlett E, New A, Perez-Rodriguez MM. The Role of Attachment Styles in the Link Between Childhood Trauma and Social Functioning in Personality Disorders Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.1152  0.357
2019 McClure MM, Graff FS, Triebwasser J, Perez-Rodriguez MM, Rosell DR, Szeszko PR, Chu KW, New AS, Siever LJ, Hazlett EA. Neuroimaging predictors of response to cognitive remediation and social skills training: A pilot study in veterans with schizophrenia. Psychiatry Research. Neuroimaging. 293: 110988. PMID 31655369 DOI: 10.1016/j.pscychresns.2019.110988  0.434
2019 Goldstein KE, Haznedar MM, Alloy LB, Drabick DAG, McClure MM, New AS, Chu KW, Vaccaro D, Tang CY, Meyerson D, Hazlett EA. Short communication: Diffusion tensor anisotropy in the cingulate in borderline and schizotypal personality disorder. Psychiatry Research. PMID 31101379 DOI: 10.1016/J.Psychres.2019.05.016  0.391
2019 McClure MM, Graff F, Triebwasser J, Perez-Rodriguez M, Rosell DR, Koenigsberg H, Hazlett EA, Siever LJ, Harvey PD, New AS. Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder. The American Journal of Psychiatry. appiajp201818030349. PMID 30654644 DOI: 10.1176/Appi.Ajp.2018.18030349  0.63
2019 McClure M, Perez-Rodriguez MM, Rosell D, Ejebe K, Siever L, New A. T38. DOPAMINE ENHANCEMENT OF VERBAL LEARNING IN THE SCHIZOPHRENIA SPECTRUM Schizophrenia Bulletin. 45: S218-S218. DOI: 10.1093/Schbul/Sbz019.318  0.386
2019 Koenigsberg H, Denny B, Lopez R, Fan J, Schulz K, Trumbull J, Lopez MM, Perez-Rodriguez M, Rosell D, New A, Hazlett E, McClure M. F149. The Effects of Cognitive Reappraisal Training to Enhance Emotion Regulation in Borderline and Avoidant Personality Disorder Patients: Evidence From Self-Reported Affect Ratings and Neuroimaging Biological Psychiatry. 85: S270-S271. DOI: 10.1016/J.Biopsych.2019.03.686  0.375
2018 Chan CC, Szeszko PR, Wong E, Tang CY, Kelliher C, Penner JD, Perez-Rodriguez MM, Rosell DR, McClure M, Roussos P, New AS, Siever LJ, Hazlett EA. Frontal and temporal cortical volume, white matter tract integrity, and hemispheric asymmetry in schizotypal personality disorder. Schizophrenia Research. PMID 29454512 DOI: 10.1016/J.Schres.2018.01.025  0.336
2018 Mercedes Perez-Rodriguez M, Rosell D, Moeller S, Kundu P, McCLure M, Hazlett E, New A. F54. PHARMACOLOGICAL ENHANCEMENT OF COGNITION AND SOCIAL COGNITION IN THE PSYCHOSIS SPECTRUM Schizophrenia Bulletin. 44: S240-S240. DOI: 10.1093/Schbul/Sby017.585  0.425
2018 Koenigsberg H, Denny B, Fan J, Galitzer H, Fels S, Rimsky L, McMaster A, New A, Perez-Rodriguez M, Hazlett E, Rosell D, McClure M. 141. Enhancing Emotion Regulation in Borderline Personality Disorder Patients Through Longitudinal Reappraisal Training: Evidence From Self-Reported Negative Affect and fMRI Biological Psychiatry. 83: S57-S58. DOI: 10.1016/J.Biopsych.2018.02.159  0.302
2017 Vella L, Patterson TL, Harvey PD, McClure MM, Mausbach BT, Taylor MJ, Twamley EW. Exploratory analysis of normative performance on the UCSD Performance-Based Skills Assessment-Brief. Psychiatry Research. 256: 150-155. PMID 28633056 DOI: 10.1016/J.Psychres.2017.06.025  0.353
2017 McClure M, Graff F, Perez-Rodriguez M, Rosell D, Hazlett E, New AS, Harvey P, Siever L. SA25. Guanfacine Augmentation of Cognitive Remediation Therapy in the Schizophrenia Spectrum: Prospects for Improving Cognitive Performance and Functional Skills Schizophrenia Bulletin. 43: S122-S122. DOI: 10.1093/Schbul/Sbx023.024  0.62
2016 Goldstein KE, Berlin HA, Hamilton HK, Mitsis EM, McClure MM, Savage KR, Blair NJ, Feder MR, Siever LJ, New AS, Hazlett EA. Cognitive and Mood Functioning in Borderline and Schizotypal Personality Disorders Psychology. 7: 292-299. DOI: 10.4236/Psych.2016.73032  0.494
2015 Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, Abi-Dargham A, Lieberman JA, Siever LJ. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 446-53. PMID 25074637 DOI: 10.1038/Npp.2014.192  0.584
2014 Hazlett EA, Lamade RV, Graff FS, McClure MM, Kolaitis JC, Goldstein KE, Siever LJ, Godbold JH, Moshier E. Visual-spatial working memory performance and temporal gray matter volume predict schizotypal personality disorder group membership. Schizophrenia Research. 152: 350-7. PMID 24398009 DOI: 10.1016/J.Schres.2013.12.006  0.494
2014 Siever LJ, Rosell D, McClure M, Strike K, Barch DM, Harvey P, Girgis R, Lieberman J, Giakoumaki S, Bitsios P, Roussos P, Haroutunian V. THE D1 RECEPTOR AND COGNITION AND TRIAL OF A NOVEL D1 AGONIST IN THE SCHIZOPHRENIA SPECTRUM Schizophrenia Research. 153: S5-S6. DOI: 10.1016/S0920-9964(14)70017-9  0.545
2014 Graff FS, McClure MM, Siever LJ. Remediation and Cognitive Enhancers in Schizotypal Personality Disorder Current Treatment Options in Psychiatry. 1: 369-375. DOI: 10.1007/s40501-014-0027-0  0.378
2013 McGurk SR, Mueser KT, Mischel R, Adams R, Harvey PD, McClure MM, Look AE, Leung WW, Siever LJ. Vocational functioning in schizotypal and paranoid personality disorders. Psychiatry Research. 210: 498-504. PMID 23932840 DOI: 10.1016/J.Psychres.2013.06.019  0.644
2013 McClure MM, Harvey PD, Bowie CR, Iacoviello B, Siever LJ. Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder. Schizophrenia Research. 144: 146-50. PMID 23375943 DOI: 10.1016/J.Schres.2012.12.012  0.724
2013 Roussos P, Bitsios P, Giakoumaki SG, McClure MM, Hazlett EA, New AS, Siever LJ. CACNA1C as a risk factor for schizotypal personality disorder and schizotypy in healthy individuals. Psychiatry Research. 206: 122-3. PMID 22985546 DOI: 10.1016/J.Psychres.2012.08.039  0.404
2012 Harvey PD, McClure MM, Patterson TL, McGrath JA, Pulver AE, Bowie CR, Siever LJ. Impairment in functional capacity as an endophenotype candidate in severe mental illness. Schizophrenia Bulletin. 38: 1318-26. PMID 21562142 DOI: 10.1093/Schbul/Sbr046  0.678
2010 McClure MM, Harvey PD, Goodman M, Triebwasser J, New A, Koenigsberg HW, Sprung LJ, Flory JD, Siever LJ. Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 1356-62. PMID 20130535 DOI: 10.1038/Npp.2010.5  0.67
2009 McClure MM, Koenigsberg HW, Reynolds D, Goodman M, New A, Trestman R, Silverman J, Harvey PD, Siever LJ. The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder. Journal of Clinical Psychopharmacology. 29: 396-8. PMID 19593186 DOI: 10.1097/Jcp.0B013E3181Accfd9  0.589
2008 McClure MM, Barch DM, Flory JD, Harvey PD, Siever LJ. Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum. Journal of Abnormal Psychology. 117: 342-54. PMID 18489210 DOI: 10.1037/0021-843X.117.2.342  0.638
2008 Bowie CR, Reichenberg A, McClure MM, Leung WL, Harvey PD. Age-associated differences in cognitive performance in older community dwelling schizophrenia patients: differential sensitivity of clinical neuropsychological and experimental information processing tests. Schizophrenia Research. 106: 50-8. PMID 18053687 DOI: 10.1016/J.Schres.2007.10.026  0.699
2008 Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, Harvey PD. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biological Psychiatry. 63: 505-11. PMID 17662256 DOI: 10.1016/J.Biopsych.2007.05.022  0.647
2007 Leung WW, McClure MM, Siever LJ, Barch DM, Harvey PD. Catechol-O-methyltransferase Val158Met genotype in healthy and personality disorder individuals: Preliminary results from an examination of cognitive tests hypothetically differentially sensitive to dopamine functions. Neuropsychiatric Disease and Treatment. 3: 925-34. PMID 19300629 DOI: 10.2147/Ndt.S1500  0.58
2007 McClure MM, Romero MJ, Bowie CR, Reichenberg A, Harvey PD, Siever LJ. Visual-spatial learning and memory in schizotypal personality disorder: continued evidence for the importance of working memory in the schizophrenia spectrum. Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists. 22: 109-16. PMID 17161580 DOI: 10.1016/J.Acn.2006.11.004  0.637
2007 McClure MM, Bowie CR, Patterson TL, Heaton RK, Weaver C, Anderson H, Harvey PD. Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships? Schizophrenia Research. 89: 330-8. PMID 16982175 DOI: 10.1016/J.Schres.2006.07.024  0.689
2007 McClure MM, Barch DM, Romero MJ, Minzenberg MJ, Triebwasser J, Harvey PD, Siever LJ. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biological Psychiatry. 61: 1157-60. PMID 16950221 DOI: 10.1016/J.Biopsych.2006.06.034  0.665
2007 McClure MM, Harvey PD. Critical issues in the assessment of disability in schizophrenia Clinical Schizophrenia and Related Psychoses. 1: 147-153. DOI: 10.3371/Csrp.1.2.3  0.551
2006 Harvey PD, McClure MM. Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. Drugs. 66: 1465-73. PMID 16906778 DOI: 10.2165/00003495-200666110-00004  0.616
2006 McClure MM, Zegarelli G, Bowie CR, Mitropoulou V, Siever LJ, Harvey PD. Cognitive impairment in the schizophrenia spectrum: What is the evidence for similarity to schizophrenia? Current Psychosis and Therapeutics Reports. 4: 128-133. DOI: 10.1007/Bf02629335  0.717
Show low-probability matches.